Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Myocarditis | New England Journal of Medicine Skip to main content The New England Journal
of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology Clinical Medicine …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …

Myocarditis is an inflammatory disease of the heart that may occur because of infections,
immune system activation, or exposure to drugs. The diagnosis of myocarditis has changed …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

The immune-related adverse events associated with treatment with immune checkpoint
inhibitors result in significant morbidity for patients as well as considerable cost to the health …

Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers.
Consistent basic data suggest that these same checkpoints are critical negative regulators of …